Abstract
Respiratory syncytial viral infections cause considerable childhood morbidity, and in some countries significant mortality, especially in infants with pre-existing conditions such as bronchopulmonary dysplasia and congenital heart disease. Currently, there is no active vaccine and attempts to prevent and ameliorate the effects of infection are focused on passive immunization by human monoclonal antibodies. This review focuses on the clinical sequelae of respiratory syncytial viral infections in high-risk patients and discusses the effects of public health measures and passive immunization on medical and socioeconomic outcomes.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.